News | September 24, 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Globally, BRUKINSA is approved in more than 70 countries
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Subscribe To Our Newsletter & Stay Updated
